×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Compliance, Potential Financial Implications, and Impact of New Safety Measures
Session Chair(s)
John Whitebrook, PhD
Partner
Deloitte MCS Ltd., United Kingdom
Good Pharmacovigilance Practices (GVP): The Real Impacts and Consequences
Learning Objective : Discuss how safety measures can increase productivity while containing costs; Identify how to involve, and collaborate with, external groups such as patients; Discuss the impacts of Good Pharmacovigilance Practices (GVP) on industry; Gain insights into pragmatic approaches to deal with GVP in the real world.
Speaker(s)
Good Pharmacovigilance Practices (GVP): The Real Impacts and Consequences
John Whitebrook, PhD
Deloitte MCS Ltd., United Kingdom
Partner
Industry Perspective
Peter Honig, MD, MPH, FACP
Advisor and Board Member, United States
Financial Implications of Drug Safety Measures and a Potential Remedy
Tatsuo Kurokawa, DIAFellow, PhD
The Japan Biosimilar Association, Japan
Director General
Have an account?